Tags

Type your tag names separated by a space and hit enter

Sildenafil citrate (Viagra) in the treatment of men with erectile dysfunction in southern Latin America: a double-blind, randomized, placebo-controlled, parallel-group, multicenter, flexible-dose escalation study.
Int J Impot Res. 2002 Aug; 14 Suppl 2:S33-41.IJ

Abstract

Our objectives were: (1) to determine the efficacy, safety, and tolerability of sildenafil citrate (Viagra) administered to men with broad-spectrum erectile dysfunction (ED) in southern Latin America; and (2) to correlate Rigiscan measurements assessing ED etiology with the investigator's assessment. A total of 141 men with broad-spectrum ED (mean age 57) were enrolled in a randomized, 12-week, double-blind, placebo-controlled, flexible-dose escalation study of sildenafil. After the 12-week treatment period, the mean score for the primary efficacy variables had risen significantly: for the sildenafil group, 66.2% from baseline for question 3 of the International Index of Erectile Function and 77.6% for question 4, vs 15.1% and 21.2% for the placebo group, respectively (P<0.0001). Rigiscan data confirmed investigator assessments of etiology. Headache and flushing, usually mild and transient, were the most common adverse events. Sildenafil was an effective, well-tolerated treatment for men in southern Latin America with broad-spectrum ED.

Authors+Show Affiliations

Centro de Diagnóstico Urológico, Buenos Aires, Argentina. ebecher@edu.com.arNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12161766

Citation

Becher, E, et al. "Sildenafil Citrate (Viagra) in the Treatment of Men With Erectile Dysfunction in Southern Latin America: a Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter, Flexible-dose Escalation Study." International Journal of Impotence Research, vol. 14 Suppl 2, 2002, pp. S33-41.
Becher E, Tejada Noriega A, Gomez R, et al. Sildenafil citrate (Viagra) in the treatment of men with erectile dysfunction in southern Latin America: a double-blind, randomized, placebo-controlled, parallel-group, multicenter, flexible-dose escalation study. Int J Impot Res. 2002;14 Suppl 2:S33-41.
Becher, E., Tejada Noriega, A., Gomez, R., & Decia, R. (2002). Sildenafil citrate (Viagra) in the treatment of men with erectile dysfunction in southern Latin America: a double-blind, randomized, placebo-controlled, parallel-group, multicenter, flexible-dose escalation study. International Journal of Impotence Research, 14 Suppl 2, S33-41.
Becher E, et al. Sildenafil Citrate (Viagra) in the Treatment of Men With Erectile Dysfunction in Southern Latin America: a Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter, Flexible-dose Escalation Study. Int J Impot Res. 2002;14 Suppl 2:S33-41. PubMed PMID: 12161766.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sildenafil citrate (Viagra) in the treatment of men with erectile dysfunction in southern Latin America: a double-blind, randomized, placebo-controlled, parallel-group, multicenter, flexible-dose escalation study. AU - Becher,E, AU - Tejada Noriega,A, AU - Gomez,R, AU - Decia,R, AU - ,, PY - 2002/8/6/pubmed PY - 2003/1/23/medline PY - 2002/8/6/entrez SP - S33 EP - 41 JF - International journal of impotence research JO - Int. J. Impot. Res. VL - 14 Suppl 2 N2 - Our objectives were: (1) to determine the efficacy, safety, and tolerability of sildenafil citrate (Viagra) administered to men with broad-spectrum erectile dysfunction (ED) in southern Latin America; and (2) to correlate Rigiscan measurements assessing ED etiology with the investigator's assessment. A total of 141 men with broad-spectrum ED (mean age 57) were enrolled in a randomized, 12-week, double-blind, placebo-controlled, flexible-dose escalation study of sildenafil. After the 12-week treatment period, the mean score for the primary efficacy variables had risen significantly: for the sildenafil group, 66.2% from baseline for question 3 of the International Index of Erectile Function and 77.6% for question 4, vs 15.1% and 21.2% for the placebo group, respectively (P<0.0001). Rigiscan data confirmed investigator assessments of etiology. Headache and flushing, usually mild and transient, were the most common adverse events. Sildenafil was an effective, well-tolerated treatment for men in southern Latin America with broad-spectrum ED. SN - 0955-9930 UR - https://www.unboundmedicine.com/medline/citation/12161766/Sildenafil_citrate__Viagra__in_the_treatment_of_men_with_erectile_dysfunction_in_southern_Latin_America:_a_double_blind_randomized_placebo_controlled_parallel_group_multicenter_flexible_dose_escalation_study_ L2 - http://dx.doi.org/10.1038/sj.ijir.3900896 DB - PRIME DP - Unbound Medicine ER -